Tag Archives: Eisai Europe Limited

Life Extending Metastatic Breast Cancer Treatment Halaven(R) (Eribulin) Launches in the United Arab Emirates

HATFIELD, England, April 22, 2015 / PRNewswire — Halaven(R) (eribulin) launches today in the United Arab Emirates (UAE) for the treatment of women with locally advanced or metastatic breast cancer (MBC). Eribulin is a life extending treatment for women with

Life-extending Advanced Breast Cancer Treatment Halaven(R) (Eribulin Mesylate) Launched in Kingdom of Saudi Arabia

HATFIELD, England, February 26, 2015 / PRNewswire / Asianet-Pakistan – - For EMEA media only: not for Swiss/U.S. Journalists Innovative breast cancer treatment Halaven(R) (eribulin mesylate) has recently been approved by the Saudi Food and Drug Authority (SFDA) for the

Eisai Announces Partnership With Newbridge to Market Breast Cancer Treatment Halaven(R) (Eribulin) Across the Middle East

HATFIELD, England, November 18, 2013/PRNewswire-FirstCall / Asianet-Pakistan – Eisai announces today that Halaven(R) (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania)

Eisai Announces Availability of Halaven® (eribulin) in Kuwait

HATFIELD, England, July 29, 2013 / PRNewswire / Asianet-Pakistan –Partnership deal secured with Yiaco for Kuwait distribution Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) today announces its partnership with Kuwait’s leading pharmaceutical marketing agency, Yiaco Medical Company,